Pharma BD Deal Intelligence

Merck KGaA / Bio-Techne Corporation

2026 · Acquisition/Merger · $11.3B · Pending

Merck KGaA, Darmstadt, Germany agreed to acquire Bio-Techne Corporation for USD 73.00 per share in cash, an enterprise value of approximately USD 11.3 billion (EUR 9.9 billion) and a 36 percent premium to Bio-Techne's one-month volume weighted average trading price. The transaction expands Merck's Life Science Services and research-reagents position. It is funded from existing cash on hand plus proceeds from new debt, was approved by Bio-Techne's board and the relevant Merck KGaA corporate bodies, and remains subject to Bio-Techne shareholder approval and regulatory clearances. Merck guided to closing by late 2026 or early 2027 and to approximately EUR 140 million of cost savings three years after closing.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Merck KGaA deals